KARACHI: The Competition Commission of Pakistan (CCP) has authorised Citi Pharma Limited’s proposed acquisition of 100 percent shareholding in Pakheim International Pharma (Private) Limited, determining that the transaction does not raise competition concerns.
In a material information notice submitted to the Pakistan Stock Exchange (PSX) on October 16, Citi Pharma said it had received the CCP’s order dated October 9, 2026, authorising the proposed acquisition under Section 31(1)(d)(i) of the Competition Act, 2010.
Citi Pharma said the acquisition would proceed in accordance with the terms of the Share Purchase Agreement dated May 6, 2026, subject to completion of the applicable legal, regulatory and other formalities.
The company added that it would make further disclosures, as required, upon completion of the relevant transaction milestones.
Copyright Business Recorder, 2026
Comments